Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 3
1977 12
1978 6
1979 7
1980 4
1981 8
1982 4
1983 23
1984 10
1985 14
1986 11
1987 16
1988 21
1989 26
1990 19
1991 17
1992 22
1993 9
1994 13
1995 11
1996 9
1997 25
1998 12
1999 14
2000 12
2001 18
2002 8
2003 13
2004 9
2005 5
2006 10
2007 9
2008 7
2009 6
2010 9
2011 6
2012 4
2013 3
2014 2
2015 2
2016 3
2017 3
2018 11
2019 6
2020 11
2021 13
2022 11
2023 9
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

490 results

Results by year

Filters applied: . Clear all
Page 1
Update on Treatment of Infantile Hemangiomas: What's New in the Last Five Years?
Macca L, Altavilla D, Di Bartolomeo L, Irrera N, Borgia F, Li Pomi F, Vaccaro F, Squadrito V, Squadrito F, Vaccaro M. Macca L, et al. Front Pharmacol. 2022 May 26;13:879602. doi: 10.3389/fphar.2022.879602. eCollection 2022. Front Pharmacol. 2022. PMID: 35721150 Free PMC article. Review.
Treatment of IHs with labeled drugs, such as oral propranolol, but also with off-label drugs, such as topical beta-blockers, including topical timolol and carteolol, steroids, itraconazole or sirolimus, with a focus on formulations types and adverse events were described i …
Treatment of IHs with labeled drugs, such as oral propranolol, but also with off-label drugs, such as topical beta-blockers, including topic …
Carteolol.
[No authors listed] [No authors listed] 2021 Sep 20. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2021 Sep 20. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000575 Free Books & Documents. Review.
No data are available for the use of carteolol during breastfeeding. Because its excretion into breastmilk is probably extensive, other beta-adrenergic blocking drugs are preferred to oral carteolol while breastfeeding a neonate. Infants over 2 months of age have mo …
No data are available for the use of carteolol during breastfeeding. Because its excretion into breastmilk is probably extensive, oth …
Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis.
Li T, Lindsley K, Rouse B, Hong H, Shi Q, Friedman DS, Wormald R, Dickersin K. Li T, et al. Ophthalmology. 2016 Jan;123(1):129-40. doi: 10.1016/j.ophtha.2015.09.005. Epub 2015 Oct 31. Ophthalmology. 2016. PMID: 26526633 Free PMC article. Review.
The mean reductions (95% credible intervals) in IOP in millimeters of mercury at 3 months ordered from the most to least effective drugs were as follows: bimatoprost 5.61 (4.94; 6.29), latanoprost 4.85 (4.24; 5.46), travoprost 4.83 (4.12; 5.54), levobunolol 4.51 (3.85; 5.24), taf …
The mean reductions (95% credible intervals) in IOP in millimeters of mercury at 3 months ordered from the most to least effective drugs wer …
Drugs for common eye disorders.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2019 Dec 2;61(1586):187-194. Med Lett Drugs Ther. 2019. PMID: 31770361 Review. No abstract available.
Dose- and Time-Dependent Cytotoxicity of Carteolol in Corneal Endothelial Cells and the Underlying Mechanisms.
Su W, Zhao J, Fan TJ. Su W, et al. Front Pharmacol. 2020 Mar 6;11:202. doi: 10.3389/fphar.2020.00202. eCollection 2020. Front Pharmacol. 2020. PMID: 32210806 Free PMC article.
Carteolol is a non-selective beta-adrenoceptor antagonist used for the treatment of glaucoma, and its abuse might be cytotoxic to the cornea. ...These observations suggested that low-dose carteolol could induce apoptosis via a caspase activated and mitochondrial-dep …
Carteolol is a non-selective beta-adrenoceptor antagonist used for the treatment of glaucoma, and its abuse might be cytotoxic to the …
Ocular carteolol: a review of its use in the management of glaucoma and ocular hypertension.
Henness S, Swainston Harrison T, Keating GM. Henness S, et al. Drugs Aging. 2007;24(6):509-28. doi: 10.2165/00002512-200724060-00007. Drugs Aging. 2007. PMID: 17571916 Review.
The new long-acting formulation of once-daily carteolol has equivalent efficacy to the standard formulation of carteolol administered twice daily in patients with OAG or OH. ...Thus, twice-daily carteolol is a well established option in the treatment of glauc …
The new long-acting formulation of once-daily carteolol has equivalent efficacy to the standard formulation of carteolol admin …
Two new drugs for glaucoma.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2018 Jul 16;60(1551):117-120. Med Lett Drugs Ther. 2018. PMID: 30036347 No abstract available.
Comparison of the Effect on Vessel Density and RNFL between Carteolol and Latanoprost.
Nutterova E, Fus M, Bartosova L, Klimesova I, Lestak J. Nutterova E, et al. J Clin Med. 2022 Jul 18;11(14):4159. doi: 10.3390/jcm11144159. J Clin Med. 2022. PMID: 35887923 Free PMC article.

Methods: The first group with diagnosed HTG consisted of 46 eyes treated with carteolol; the second group consisted of 52 eyes treated with latanoprost. ...In contrast, the change in the VD parameter was statistically significant between groups (p < 0.05), with a greate

…
Methods: The first group with diagnosed HTG consisted of 46 eyes treated with carteolol; the second group consisted of 52 eyes treate …
A Review of the Pharmacological Properties of 3,4-dihydro-2(1H)- quinolinones.
Meiring L, Petzer JP, Petzer A. Meiring L, et al. Mini Rev Med Chem. 2018;18(10):828-836. doi: 10.2174/1389557517666170927141323. Mini Rev Med Chem. 2018. PMID: 28971767 Review.
The 3,4-dihydro-2(1H)-quinolinone moiety is present in a number of pharmacologically active compounds. These include FDA approved drugs such as cilostazol, carteolol and aripiprazole as well as numerous experimental compounds. ...
The 3,4-dihydro-2(1H)-quinolinone moiety is present in a number of pharmacologically active compounds. These include FDA approved drugs such …
Ocular carteolol. A review of its pharmacological properties, and therapeutic use in glaucoma and ocular hypertension.
Chrisp P, Sorkin EM. Chrisp P, et al. Drugs Aging. 1992 Jan-Feb;2(1):58-77. doi: 10.2165/00002512-199202010-00007. Drugs Aging. 1992. PMID: 1554974 Review.
Carteolol is a relatively potent nonselective beta-adrenoceptor antagonist with partial agonist activity. ...Carteolol eyedrops lack local anaesthetic activity, appear to cause less local irritation than timolol, and produce less pronounced decreases in heart rate o …
Carteolol is a relatively potent nonselective beta-adrenoceptor antagonist with partial agonist activity. ...Carteolol eyedrop …
490 results